You searched for - Page 358 of 412 - Institute for Bioengineering of Catalonia

PhD thesis defence: Juan Pablo Agusil

Fabrication of (bio)molecular patterns with contact printing techniques

IBEC group leader a fem.talent award winner

IBEC group leader Alicia Casals received a 2015 fem.talent Award at the fem.talent Fòrum in Barcelona on Friday.

Alicia (third from right) won the prize for “Career trajectory”, recognising such milestones as the creation in 2011 of IBEC/UPC spin-off Rob Surgical Systems. Other award categories were “Emerging Talent”, “Innovation” and “Communication”.

The forum is a yearly conference of fem.talent, an initiative of the Network of Science and Technology Parks of Catalonia (XPCAT) that aims to promote equality of opportunity between men and women. This year the theme was “Smart Time: intelligent management of time,” with the objective of discussing innovative ideas and different practices in the field of time management.

Convergència representatives visit IBEC

On Friday morning representatives of Catalan political party Convergència i Unió (CIU) visited IBEC as part of a tour of the PCB.

Congresswoman Imma Riera and organizational secretary Josep Rull met IBEC Director Josep Samitier, who gave them an overview of IBEC, before visiting the Nanotechnology Platform, guided by coordinator Mateu Pla.

A two-page article in La Vanguardia today talks about biomimetics and how scientists are replicating processes from nature in fields such as nanotechnology, engineering, robotics, chemistry and materials science.

“Robots del tamaño de virus”

El Periódico features an interview with Samuel Sànchez following the announcement last week that he has been awarded the Premio Fundación Princesa de Girona Investigación Científica 2015.

Eduard Torrents, who heads IBEC’s Bacterial infections: antimicrobial therapies group, is the subject of an article in the Diari de Terrassa this week about his work earlier this year which identified a important factor in E. coli infection, opening the way to developing targeted drugs against the potentially deadly condition.